Abstract
Background
To evaluate the relationship between prostate volume (PV) and diabetes mellitus (DM) in geriatric benign prostatic hyperplasia (BPH) patients.
Methods
One hundred and seventeen geriatric patients with BPH were retrospectively studied between 2008 and 2009. Patients were divided into two groups: BPH and BPH with DM group. The effects of indexes of DM, including fasting blood glucose (FBG), 2-h postprandial blood glucose, glycosylated hemoglobin (HbA1c), fasting insulin (FINS), insulin resistance (IR) index, prostate-specific antigen (PSA), International Prostate Symptom Score (IPSS), and lower urinary tract symptoms (LUTS) were evaluated.
Results
The values of PV (P = 0.005), PSA (P = 0.013), and IPSS (P = 0.01) in the BPH patients with DM group were significantly higher than in the BPH group. The values of PV (P = 0.002) and PSA (P = 0.006) in the BPH patients with elevated FBG were significantly higher than in the BPH patients with normal FBG. BPH patients with elevated HbA1c had significantly higher PV than BPH patients with normal HbA1c (P = 0.046). BPH with hyperinsulinemia group showed significantly higher PV (P = 0.017) and longer duration of LUTS (P = 0.031) than BPH patients with normal FINS. Similarly, BPH patients with IR had higher PV (P = 0.004) and longer duration of LUTS (P = 0.036) than BPH patients without IR. The logistic regression analysis showed that FBG and FINS were the risk factors for BPH.
Conclusions
Our study demonstrates that PV is closely correlated with diabetes and diabetes has a direct effect on the occurrence and development of BPH.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gupta A, Gupta S, Pavuk M, Roehrborn CG (2006) Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 68:1198–1205
Sarma AV, Parsons JK, McVary K, Wei JT (2009) Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms—what do we know? J Urol 182:S32–S37
Holtgrewe HL (1995) Economic issues and the management of benign prostatic hyperplasia. Urology 46:23–25
Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46:547–554
American Diabetes Association (2009) Standards of medical care in diabetes 2009. Diabetes Care 32(Suppl 1):S13–S61
Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495
Matthews GJ, Motta J, Fracehia JA (1996) The accuracy of transrectal ultrasound prostate volume estimation: clinical correlations. J Clin Ultrasound 24:501–505
World Health Organization (1998) Obesity, Preventing and managing the global epidemic. WHO/NUT Geneva 98:234–236
Mc Connell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398
Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ et al (2006) Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91:2562–2568
Kim WT, Yun SJ, Choi YD, Kim GY, Moon SK et al (2011) Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels. J Korean Med Sci 26:1214–1218
Alvinc P (2005) Diabetes mellitus. In: Dennis LK, Eugene B, Anthonys F, Stephen LH et al (eds) Harrison’s principles of internal medicine, 16th edn. McGraw-Hill: Medical Publishing Division, New York, pp 2152–2180
Vikram A, Jena GB, Ramarao P (2010) Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate 70:79–89
Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW (2002) Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 168:599–604
Hammarsten J, Högstedt B (2001) Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39:151–158
Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA et al (1994) Obesity and benign prostatic hyperplasia. Am J Epidemiol 140:989–1002
Bourke JB, Griffin JP (1966) Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br J Urol 38:18–23
Standl E (1995) Hyperinsulinemia and atherosclerosis. Clin Invest Med 18:261–266
Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O et al (2006) Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 98:1038–1042
Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S et al (2007) The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51:199–203; discussion 204–206
Acknowledgments
This work was supported by grants from China Central Commission of Health Care (B2009A058), Key Research Project of Changsha City (K0902169-31), Science and Technology Department of Hunan province (2009FJ3076).
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Qu, X., Huang, Z., Meng, X. et al. Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients. Int Urol Nephrol 46, 499–504 (2014). https://doi.org/10.1007/s11255-013-0555-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-013-0555-3